What is the MoonLake Immunotherapeutics stock price forecast?

MoonLake Immunotherapeutics is currently trading at $18.98. View real-time AI analysis on Alpha Lenz.

What is MoonLake Immunotherapeutics insider trading activity?

View the latest insider trading data for MoonLake Immunotherapeutics on Alpha Lenz.

What is MoonLake Immunotherapeutics's P/E ratio?

MoonLake Immunotherapeutics's P/E ratio is -5.4.

MoonLake Immunotherapeutics

NASDAQ · MLTX

$18.98-0.21(-1.09%)Pre-market

Ask about MoonLake Immunotherapeutics's future dividend policy...

Alpha Chat Insight

“MoonLake Immunotherapeutics trades at a P/E of -5.4 (undervalued) with modest ROE of -60.5%.”

Ask for details →

Company Overview

MoonLake Immunotherapeutics is a biotechnology company focused on developing and advancing treatments for inflammatory conditions. Leveraging cutting-edge Sonelokimab technology, MoonLake aims to provide innovative solutions in managing diseases such as hidradenitis suppurativa, psoriatic arthritis, and ankylosing spondylitis. The company specializes in next-generation nanobody therapeutics that promise enhanced treatment efficacy and patient outcomes. In the biotechnology and healthcare sectors, MoonLake plays a significant role by addressing unmet medical needs and spearheading advances in therapeutic approaches. By collaborating with global research institutions and leveraging proprietary technology, MoonLake Immunotherapeutics significantly contributes to the development of novel medical therapies. The company's focus on inflammatory diseases highlights its commitment to improving the quality of life for patients worldwide, situating it as a pivotal player in the biopharmaceutical landscape.

CEODr. Jorge Santos da Silva Ph.D.

Websitehttps://www.moonlaketx.com

SectorHealthcare

IndustryBiotechnology

Employees100

Company Statistics

FY 2025

Profile

$1.22BMarket Cap

$0.00Revenue

0.00Shares Out

100Employees

Margins

N/AGross

N/AEBITDA

N/AOperating

N/APre-Tax

N/ANet

Valuation

-5.38P/E

4.02P/B

N/AEV/Sales

-4.39EV/EBITDA

-6.24P/FCF

Growth (CAGR)

N/ARev 3Yr

N/ARev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-51.05%ROA

-60.51%ROE

-49.31%ROIC

Financial Health

$334.52MCash & Cash Equivalents

$-214.56MNet Debt

39.40%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“MoonLake Immunotherapeutics trades at a P/E of -5.4 (undervalued) with modest ROE of -60.5%.”

Ask for details →

Frequently Asked Questions

MoonLake Immunotherapeutics (ticker: MLTX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 100 employees. Market cap is $1.2B.

The current price is $18.98 with a P/E ratio of -5.38x and P/B of 4.02x.

ROE is -60.51%.